Christopher Gasink

5.0k total citations · 1 hit paper
91 papers, 2.2k citations indexed

About

Christopher Gasink is a scholar working on Genetics, Surgery and Epidemiology. According to data from OpenAlex, Christopher Gasink has authored 91 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Genetics, 38 papers in Surgery and 36 papers in Epidemiology. Recurrent topics in Christopher Gasink's work include Inflammatory Bowel Disease (80 papers), Eosinophilic Esophagitis (25 papers) and Microscopic Colitis (25 papers). Christopher Gasink is often cited by papers focused on Inflammatory Bowel Disease (80 papers), Eosinophilic Esophagitis (25 papers) and Microscopic Colitis (25 papers). Christopher Gasink collaborates with scholars based in United States, Canada and Belgium. Christopher Gasink's co-authors include William J. Sandborn, Brian G. Feagan, Subrata Ghosh, Bruce E. Sands, Jewel Johanns, Paul Rutgeerts, Willem J.S. de Villiers, Omoniyi J. Adedokun, Stephan R. Targan and Stephen B. Hanauer and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Gut.

In The Last Decade

Christopher Gasink

83 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

2012 838 citations William J. Sandborn, Christopher Gasink et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Gasink United States	17	1.8k	1.1k	958	604	177	91	2.2k
Satoshi Motoya Japan	21	961 0.5×	732 0.7×	367 0.4×	330 0.5×	92 0.5×	65	1.4k
Charlotte Magdelaine–Beuzelin France	10	823 0.5×	626 0.6×	484 0.5×	178 0.3×	121 0.7×	11	1.3k
Colleen McElree United States	10	1.1k 0.6×	518 0.5×	545 0.6×	491 0.8×	40 0.2×	11	1.5k
Allison Luo United States	13	348 0.2×	307 0.3×	416 0.4×	131 0.2×	160 0.9×	30	1.0k
J. Mark Farrant United Kingdom	13	753 0.4×	816 0.7×	169 0.2×	839 1.4×	38 0.2×	18	1.7k
Zdena Zádorová Czechia	8	407 0.2×	312 0.3×	318 0.3×	215 0.4×	60 0.3×	12	861
Pascale Loiseau France	22	214 0.1×	210 0.2×	753 0.8×	148 0.2×	412 2.3×	45	1.6k
Thierry Lazure France	16	217 0.1×	116 0.1×	496 0.5×	351 0.6×	113 0.6×	67	1.5k
Isabelle Radford‐Weiss France	16	139 0.1×	341 0.3×	358 0.4×	187 0.3×	316 1.8×	31	1.1k
Etsuko Maruya Japan	24	240 0.1×	142 0.1×	790 0.8×	323 0.5×	738 4.2×	72	1.8k

Countries citing papers authored by Christopher Gasink

Since Specialization

Citations

This map shows the geographic impact of Christopher Gasink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Gasink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Gasink more than expected).

Fields of papers citing papers by Christopher Gasink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Gasink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Gasink. The network helps show where Christopher Gasink may publish in the future.

Co-authorship network of co-authors of Christopher Gasink

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Gasink. A scholar is included among the top collaborators of Christopher Gasink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Gasink. Christopher Gasink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ghosh, Subrata, Brian G. Feagan, Elyssa Ott, et al.. (2024). Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis. Journal of Crohn s and Colitis. 18(7). 1091–1101. 17 indexed citations

Colombel, Jean‐Frédéric, Bruce E. Sands, Christopher Gasink, et al.. (2023). Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology. 22(1). 144–153.e2. 5 indexed citations

Lee, Scott D., Stefan Schreiber, C. Janneke van der Woude, et al.. (2023). 1027 EFFICACY AND SAFETY OF INTRAVENOUS USTEKINUMAB REINDUCTION THERAPY IN CROHN'S DISEASE PATIENTS WITH SECONDARY LOSS OF RESPONSE TO USTEKINUMAB MAINTENANCE THERAPY: WEEK 16 RESULTS FROM THE POWER TRIAL. Gastroenterology. 164(6). S–220. 3 indexed citations

Abraham, Bincy, Elyssa Ott, Lindsay Miller, et al.. (2022). Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn’s Disease and 2 Years in Ulcerative Colitis. Crohn s & Colitis 360. 4(3). otac025–otac025. 11 indexed citations

Panaccione, Remo, Christopher Gasink, Timothy Hoops, et al.. (2022). O30 Closure of perianal fistula in patients receiving ustekinumab in the SEAVUE and STARDUST trials. Oral Presentations. A17–A17. 2 indexed citations

Panaccione, Remo, Bruce E. Sands, Silvio Danese, et al.. (2022). Tu1445: EFFECT OF PHARMACOKINETICS AND IMMUNOGENICITY ON CLINICAL AND ENDOSCOPIC EFFICACY IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SEAVUE STUDY. Gastroenterology. 162(7). S–963. 1 indexed citations

Adedokun, Omoniyi J., et al.. (2022). Population Pharmacokinetics and Exposure–Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease. Clinical Therapeutics. 44(10). 1336–1355. 23 indexed citations

Sandborn, William J., Yuhua Wang, Bin Zou, et al.. (2021). Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial. Clinical Gastroenterology and Hepatology. 20(3). 578–590.e4. 149 indexed citations

Lewis, James D., Matthieu Allez, Peter M. Irving, et al.. (2021). S851 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: PROMIS-29 in the SEAVUE Study. The American Journal of Gastroenterology. 116(1). S395–S395. 1 indexed citations

10.

Sandborn, William J., Brian G. Feagan, Silvio Danese, et al.. (2020). Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Inflammatory Bowel Diseases. 27(7). 994–1007. 77 indexed citations

11.

Sands, Bruce E., Chenglong Han, Christopher Gasink, et al.. (2019). 690 Ustekinumab Maintained Clinically Meaningful Improvement in Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease: Results From the IM-UNITI Long-Term Extension. The American Journal of Gastroenterology. 114(1). S404–S404. 1 indexed citations

12.

Li, Katherine, Joshua R. Friedman, Daphne Chan, et al.. (2019). Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn’s Disease. Gastroenterology. 157(4). 1019–1031.e7. 48 indexed citations

13.

Adedokun, Omoniyi J., Zhenhua Xu, Christopher Gasink, et al.. (2018). Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 154(6). 1660–1671. 179 indexed citations

14.

Rutgeerts, Paul, Christopher Gasink, Daphne Chan, et al.. (2018). Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease. Gastroenterology. 155(4). 1045–1058. 115 indexed citations

15.

Colombel, Jean‐Frédéric, Omoniyi J. Adedokun, Christopher Gasink, et al.. (2018). Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clinical Gastroenterology and Hepatology. 17(8). 1525–1532.e1. 126 indexed citations

16.

Sands, Bruce E., et al.. (2018). Ustekinumab Improves Productivity and Reduces Work Limitation of Patients With Moderate to Severe Crohnʼs Disease: Results From Three Phase 3 Clinical Trials. The American Journal of Gastroenterology. 113(Supplement). S352–S352. 1 indexed citations

17.

Sands, Bruce E., Christopher Gasink, Lizhen Gao, et al.. (2017). OC-045 Efficacy & safety of dose adjustment & delayed response to ustekinumab in moderate–severe crohn’s disease patients: results from im-uniti maintenance study. HighWire Press Open Archive. A23.1–A23. 6 indexed citations

18.

Scherl, Ellen, et al.. (2017). Pregnancy Outcomes in Women Exposed to Ustekinumab in the Crohnʼs Disease Clinical Development Program. The American Journal of Gastroenterology. 112. S332–S333. 1 indexed citations

19.

Sandborn, William J., Christopher Gasink, Marion Blank, et al.. (2012). Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease. New England Journal of Medicine. 367(16). 1519–1528. 838 indexed citations breakdown →

20.

Han, Chenglong, et al.. (2010). 43 Impact of Psychiatric Disorders on Patients With Crohn's Disease: An Analysis Based on a Healthcare Claims Database. Gastroenterology. 138(5). S–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact